Analyst Reco. Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Real-time Estimate Cboe BZX Other stock markets 11:20:16 2024-05-13 am EDT			5-day change	1st Jan Change
4.235 ^USD	+2.05%		+9.51%	-0.70%

May. 08	BofA Securities Starts Sutro Biopharma With Buy Rating	MT
Apr. 30	Sutro Biopharma, Inc. Announces Initiation of Randomized Portion (Part 2) of REFRaME-O1 Trial	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BofA Securities Starts Sutro Biopharma With Buy Rating	May. 08	MT
Piper Sandler Trims Price Target on Sutro Biopharma to $11 From $12, Maintains Overweight Rating	Apr. 03	MT
Truist Securities Adjusts Price Target on Sutro Biopharma to $18 From $25, Keeps Buy Rating	Apr. 03	MT
Wedbush Adjusts Sutro Biopharma's Price Target to $8 From $12, Maintains Outperform Rating	Mar. 26	MT
Piper Sandler Adjusts Price Target on Sutro Biopharma to $12 From $18, Maintains Overweight Rating	Nov. 15	MT
Oppenheimer Initiates Coverage on Sutro Biopharma With Outperform Rating, $10 Price Target	23-10-06	MT
Wedbush Cuts Sutro Biopharma's PT to $12 From $20, Pushes Back Estimated Launch of STRO-002, Adjusts Capital Raise Assumptions; Keeps Outperform Rating	23-08-11	MT
JMP Securities Adjusts Price Target on Sutro Biopharma to $17 From $20, Maintains Market Outperform Rating	23-04-03	MT
HC Wainwright Adjusts Price Target on Sutro Biopharma to $16 From $20, Keeps Buy Rating	23-03-31	MT
Truist Securities Adjusts Sutro Biopharma's Price Target to $25 From $21, Keeps Buy Rating	23-01-13	MT
Piper Sandler Adjusts Price Target on Sutro Biopharma to $18 From $16, Maintains Overweight Rating	23-01-10	MT
HC Wainwright Cuts Price Target on Sutro Biopharma to $20 From $30, Affirms Buy Rating	22-11-09	MT
Truist Securities Adjusts Sutro Biopharma Price Target to $21 From $37, Maintains Buy Rating	22-08-23	MT
Berenberg Bank Adjusts Sutro Biopharma's Price Target to $26 From $30, Maintains Buy Rating	22-08-09	MT
Piper Sandler Reduces Sutro Biopharma's Price Target to $14 From $29, Reiterates Overweight Rating	22-05-23	MT
Piper Sandler Adjusts Sutro Biopharma Price Target to $14 From $29, Maintains Overweight Rating	22-05-23	MT
Wedbush Cuts Sutro Biopharma's Price Target to $20 From $30, Citing Launch Timelines, Cost of Capital; Outperform Rating Kept	22-05-10	MT
JMP Securities Adjusts Sutro Biopharma's Price Target to $20 From $28, Maintains Market Outperform Rating	22-03-07	MT
Wedbush Cuts Sutro Biopharma's Price Target to $30 From $37, Citing Adjusted Timelines for STRO-001, -002; Outperform Rating Kept	22-01-06	MT
Sutro Early-Stage Ovarian Cancer Study Shows 33% Objective Response Rate -- Shares Drop in Pre-Market Trading	22-01-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Analyst Reco.

Filters